Charles River Laboratories (CRL) Tops Q4 EPS by 10c, Guides FY17 EPS In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Charles River Labs (CRL) PT Raised to $84 at UBS Following Strong 4Q Results
February 15, 2017 9:31 AM ESTUBS analyst Jonathan Groberg maintains Sell rating and raises price target on Charles River Laboratories International (NYSE: CRL) to $84 (from $78), as the company announced revenue and EPS figures above consensus projections.
Groberg comments, "CRL reported 4Q16 results with reported revenue of $467m,... More
Charles River Labs (CRL) PT Raised to $104 at Jefferies Following Strong 4Q Results
February 15, 2017 8:11 AM ESTJefferies analyst David Windley reiterates Buy rating and raises price target on Charles River Laboratories (NYSE: CRL), as the company reported 2016 fourth quarter revenue and EPS above consensus.
Windley comments, "4Q results far outpaced consensus revenue/EPS driven by strength across the 3 segments.... More
